These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22444679)

  • 21. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
    Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
    Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
    Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
    Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.
    Catena R; Luis-Ravelo D; Antón I; Zandueta C; Salazar-Colocho P; Larzábal L; Calvo A; Lecanda F
    Cancer Res; 2011 Jan; 71(1):164-74. PubMed ID: 21097719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
    Di Desidero T; Fioravanti A; Orlandi P; Canu B; Giannini R; Borrelli N; Man S; Xu P; Fontanini G; Basolo F; Kerbel RS; Francia G; Danesi R; Bocci G
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1465-73. PubMed ID: 23969186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting the α
    Sartori A; Portioli E; Battistini L; Calorini L; Pupi A; Vacondio F; Arosio D; Bianchini F; Zanardi F
    J Med Chem; 2017 Jan; 60(1):248-262. PubMed ID: 27997164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
    Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
    Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase.
    Wang JQ; Miller KD; Sledge GW; Zheng QH
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4380-4. PubMed ID: 16019210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells.
    Shin HW; Cho CH; Kim TY; Park JW
    Biochem Biophys Res Commun; 2010 Jul; 398(2):205-11. PubMed ID: 20599738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents.
    Yousefian M; Ghodsi R
    Arch Pharm (Weinheim); 2020 Dec; 353(12):e2000022. PubMed ID: 32885522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sunitinib on growth and function of FRTL-5 thyroid cells.
    Salem AK; Fenton MS; Marion KM; Hershman JM
    Thyroid; 2008 Jun; 18(6):631-5. PubMed ID: 18578612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
    Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.
    Gangjee A; Zaware N; Raghavan S; Disch BC; Thorpe JE; Bastian A; Ihnat MA
    Bioorg Med Chem; 2013 Apr; 21(7):1857-64. PubMed ID: 23434139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential inhibitors of angiogenesis. Part I: 3-(imidazol-4(5)-ylmethylene)indolin-2-ones.
    Braud E; Duflos M; Nourrisson MR; Tonnerre A; Picot C; Le Baut G; Renard P; Pfeiffer B; Tucker G
    J Enzyme Inhib Med Chem; 2003 Jun; 18(3):243-52. PubMed ID: 14506915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
    Roskoski R
    Biochem Biophys Res Commun; 2007 May; 356(2):323-8. PubMed ID: 17367763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunitinib--CLIO conjugate: a VEGFR/PDGFR-targeting active MR probe.
    Noh GT; Kim MH; Suh JY; Song Y; Lee CK; Baek JH; Lee YS; Cho G; Kim E; Kim YR; Cho HJ; Lim D; Kim JK
    Mol Imaging Biol; 2014 Jun; 16(3):340-9. PubMed ID: 24185817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.